Skip to main content

Wyost News

Monthly News Roundup - February 2025

FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...

Denosumab Increases Cardiovascular Risk in Dialysis-Dependent Patients

TUESDAY, Jan. 7, 2025 – For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse...

Risk for Emergently Treated Hypocalcemia With Denosumab Rises With CKD Stage

TUESDAY, Nov. 19, 2024 – For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with worsening CKD stage, according to a study...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Wyost patient information at Drugs.com